title: [Indications of anakinra].
abstract: The efficacy of anakinra on both RA-related symptoms and structural damage has been demonstrated in several randomized controlled trials. However, its interest seems limited with regards to other biologic agents. Anakinra seems promising in the treatment of childhood or adult onset Still disease, after the failure of both high dose steroids and methotrexate. The efficacy of anakinra is dramatic in several hereditary auto-inflammatory syndromes. Anakinra could be an interesting drug for the treatment of neutrophilic dermatosis or relapsing chondritis, refractory to conventional agents. Injection site reactions and infections are the 2 main anakinra-related side effects.
authors.affiliation: Service de rhumatologie, GH Pitié-Salpêtrière, AP-HP, Université Paris 6 Pierre et Marie Curie, UFR de médecine, Site Pitié-Salpêtrière, F-75013 Paris, France.
authors.forename: Karine
authors.initials: K
authors.lastname: Chauffier
authors.forename: Jonathan
authors.initials: J
authors.lastname: London
authors.forename: Constance
authors.initials: C
authors.lastname: Beaudouin
authors.forename: Bruno
authors.initials: B
authors.lastname: Fautrel
mesh_terms: D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006073:Gout / Q000188:drug therapy; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000494:pharmacology / Q000627:therapeutic use*; D011081:Polychondritis, Relapsing / Q000188:drug therapy; D016463:Sweet Syndrome / Q000188:drug therapy
chemical_list: D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein